Through the provision of these two-year collaborative research grants, the Chan Zuckerberg Initiative (CZI) programme aims to accelerate cutting-edge research and technology in metabolism and metabolic physiology. The objective of these grants is to map, measure, and integrate metabolism across different scales—from molecules and organelles to cells and tissues—deepening our understanding of human biology, and to investigate the metabolic processes that maintain physiological homeostasis.

The Champalimaud Foundation, a private non-profit research institution located in Lisbon, Portugal, has achieved a significant milestone in cancer research and pre-clinical development by obtaining exclusive rights to deploy synthetic biology technologies initially licensed from Stanford University and further developed by Refuge Biotechnologies (Refuge), a pioneering synthetic biology company specialising in cancer immunotherapy.

A novel infrastructure for storing, consulting and analysing medical data will be presented at the Open Day of the Champalimaud Foundation (FC) Breast Unit, which is taking place today, October 16. It was created by the Unit's Digital Surgery Lab, a multidisciplinary team led by surgeon Pedro Gouveia, in partnership with the telecommunications company Altice and the Portuguese company BMD Software.

A side-effect “is any effect of a drug, chemical, or other medicine that is in addition to its intended effect, especially an effect that is harmful or unpleasant”. 

Malignant melanoma is a highly aggressive form of skin cancer that is on the rise. However, recent breakthrough research has introduced new targeted therapies and immunotherapies for melanoma treatment, transforming the approach to treating melanoma and offering hope to patients with limited alternatives.